HighTower Advisors
STLN

HighTower Advisors’s Starling Oncology STLN Stock Holding History

HighTower Advisors’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$466K Buy
85,838
+1,919
+2% +$8.06K ﹤0.01% 2803
2026
Q1 		$258K Sell
83,919
-1,932
-2% -$5.92K ﹤0.01% 3295
2025
Q4 		$306K Buy
85,851
+4,489
+6% +$16.6K ﹤0.01% 3033
2025
Q3 		$284K Hold
81,362
– – ﹤0.01% 3089
2025
Q2 		$167K Hold
81,362
– – ﹤0.01% 3360
2025
Q1 		$92.8K Hold
81,362
– – ﹤0.01% 3379
2024
Q4 		$25.1K Hold
81,362
– – ﹤0.01% 3524
2024
Q3 		$27K Buy
81,362
+53,382
+191% +$22.1K ﹤0.01% 3485
2024
Q2 		$13K Hold
27,980
– – ﹤0.01% 3427
2024
Q1 		$44K Buy
+27,980
New +$53.2K ﹤0.01% 3270

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

HighTower Advisors's STLN Position: Q2 2026 in Review

HighTower Advisors increased its Starling Oncology (STLN) stake by 2.3% in Q2 2026, buying an estimated $8.06K and bringing the position to 85,838 shares worth $466K. The position accounts for ﹤0.01% of the portfolio, ranked #2803.

HighTower Advisors first reported a position in STLN in Q1 2024 and has held it in 10 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • HighTower Advisors held 85,838 shares of Starling Oncology worth $466K as of Q2 2026.
  • HighTower Advisors bought 1,919 Starling Oncology shares in Q2 2026, an estimated $8.06K.
  • Starling Oncology made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #2803 holding.
  • HighTower Advisors first reported a position in Starling Oncology in Q1 2024 and has held it in 10 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.